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Glial cellThe pro-inflammatory cytokine interleukin-1β (IL-1β) plays a key role in initiating an immune response within
the central nervous system(CNS), and is thought tobe a significant contributor to theneurodegenerative process.
The actions of IL-1β can be regulated by interleukin-1 receptor antagonist (IL-1ra), which prevents IL-1β from
acting on the IL-1 type I receptor (IL-1RI). Another negative regulator of the IL-1 system is the IL-1 type II receptor
(IL-1RII); a decoy receptor that serves to sequester IL-1. Consequently, pharmacological strategies that tip the
balance in favour of IL-1ra and IL-1RIImay be of therapeutic benefit. Evidence suggests that the neurotransmitter
noradrenaline elicits anti-inflammatory actions in the CNS, and consequently may play an endogenous
neuroprotective role. Herewe report thatnoradrenaline inducesproductionof IL-1ra and IL-1RII fromprimary rat
mixed glial cells. In contrast, noradrenaline did not alter IL-1β expression, or expression of IL-1RI or the IL-1 type I
receptor accessory protein (IL-1RAcp); both of which are required for IL-1 signalling. Our results demonstrate
that the ability of noradrenaline to induce IL-1ra and IL-1RII is mediated via β-adrenoceptor activation and
downstream activation of protein kinase A and extracellular signal-regulated kinase (ERK). In parallel with its
ability to increase IL-1ra and IL-1RII, noradrenaline prevented neurotoxicity in cortical primary neurons induced
by conditioned medium from IL-1β treated mixed glial cells. These data indicate that noradrenaline negatively
regulates IL-1 system in glial cells and has neuroprotective properties in situations where IL-1 contributes to
pathology.Neuroscience, Lloyd building,
; fax: +353 1 8963183.
l rights reserved.© 2009 Elsevier B.V. All rights reserved.1. Introduction
Evidence suggests that inflammation contributes to pathology in
neurodegenerative disease states such as Alzheimer's disease,
Parkinson's disease, Stroke and Multiple Sclerosis (Allan et al., 2005;
Block and Hong, 2005; Griffin and Mrak, 2002; Hauss-Wegrzyniak et
al., 1998; Olsson et al., 2005), and also contributes to age-related
neurodegeneration (Godbout and Johnson, 2006; Lynch and Lynch,
2002). The pro-inflammatory cytokine interleukin-1β (IL-1β) has
been implicated as a key contributor to neuronal injury (see Allan
et al., 2005; Basu et al., 2004). IL-1β signals via the IL-1 type I receptor
(IL-1RI) andassociationof the IL-1RIwith its accessoryprotein (IL-1RAcp)
(Sims et al., 1988; Korherr et al., 1997), and this signalling system is
present in the brain (Ericsson et al., 1995; Lynch and Lynch, 2002). The
biological actions of IL-1β are regulated in vivo by IL-1 receptor
antagonist (IL-1ra) (Carter et al., 1990); a molecule prevents IL-1β
from binding to IL-1RI (Lundkvist et al., 1999; Gabay et al., 1997). In
vitro, IL-1ra suppresses IL-1β-induced TNF-α production and iNOS
expression in astrocytes (Liu et al., 1996), and protects against IL-1β and
excitotoxin-induced neurotoxicity (Thornton et al., 2006). Furthermore,IL-1ra attenuates ischaemic and excitotoxic neuronal damage in vivo
(Relton andRothwell, 1992), and IL-1ra deficientmice exhibit increased
neuronal injury following cerebral ischemia (Pinteaux et al., 2006).
The actions of IL-1 are regulated by binding to the IL-1 type II
receptor (IL-1RII); a decoy receptor that sequesters IL-1β (Colotta
et al., 1994). A number of studies have described IL-1RII expression in
glial cells and in the intact brain (French et al., 1999; Parnet et al.,
1994; Pinteaux et al., 2002). Furthermore, increased central expres-
sion of IL-1RII has been reported following insults such as cerebral
ischemia (Wang et al., 1997), kainic acid administration (Nishiyori
et al., 1997) and central administration of IL-1β (Docagne et al., 2005),
most likely in an effort to limit the detrimental actions of IL-1β on
neuronal function. Whilst there is no data available on its anti-
inflammatory actions in the CNS, IL-1RII has been shown to inhibit the
actions of IL-1 in the periphery in an arthritis model (Dawson et al.,
1999). Considering the evidence, the balance between expression of
IL-1β and the negative regulators IL-1ra and IL-1RII is likely to be of
importance in combating neurodegeneration.
The monoamine neurotransmitter noradrenaline has anti-inflam-
matory properties, and plays an important role in maintaining the
immunosuppressive environment within the brain (Feinstein et al.,
2002; Marien et al., 2004). Noradrenergic innervation is widespread
throughout the brain, and following its release noradrenaline can
reach proximal glial cells (Aoki, 1992) andmodulate glial cell function
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we examined the ability of noradrenaline to alter expression of IL-1β,
IL-1ra and IL-1 receptors in rat primary mixed glial cells. Once we
established that noradrenaline induced glial IL-1ra and IL-1RII
expression, we investigated the signalling mechanisms involved.
Finally we examined the ability of noradrenaline to protect neurons
from neurotoxicity induced by conditioned media from IL-1β-
stimulated glial cells.
2. Materials and methods
2.1. Materials
Noradrenaline, propranalol, phentolamine and dibutyryl adenosine
3′,5′-cyclic monophosphate (dbcAMP) were obtained from Sigma
Chemical Co. (Poole, UK). Salmeterol and xamoterol were obtained
from Tocris, UK, (9R,10S,12S)-2,3,9,10,11,12-Hexahydro-10-hydroxy-
9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3′,2′,1′-kl]pyrrolo
[3,4-i][1,6]benzodiazocine-10-carboxylic acid, hexyl ester (KT5720)
was obtained from Calbiochem UK, and 1,4-Diamino-2,3-dicyano-1,4-
bis[2-aminophenylthio]butadiene (U0126)wasobtained fromPromega
(UK). Antibodies and standards for interleukin (IL)-1β and IL-1ra ELISA
reagents were obtained from R&D systems (UK) and Dr. Steve Poole,
NIBSC (Potters Bar, UK) respectively. Rat IL-1RII antibodywaspurchased
from Santa Cruz Biotechnology (USA) and antibodies for phosphorylat-
ed and total ERK were obtained from Cell Signalling Technologies
(Ireland). Recombinant rat IL-1βwas obtained from R&D systems (UK).
Cytotox 96® Non-Radioactive Cytotoxicity Assay was purchased from
Promega (UK). Gene expression assays for IL-1β, IL-1ra, IL-1RI, IL-1RII,
IL-1RAcp, β-actin and Taqman master mix were obtained from Applied
Biosystems. Cell culture reagents were obtained from Invitrogen
(Ireland), and all other reagents were obtained from Sigma (UK) unless
otherwise stated.
2.2. Primary cell culture
2.2.1. Preparation of cultured primary mixed glia
Primary mixed glial cultures were isolated and prepared from
1-day-old Wistar rats (BioResources Unit, Trinity College, Dublin 2,
Ireland). Briefly, the rats were decapitated, the meninges were
removed and the cortices were isolated and dissociated in sterile
PBS. The cortices were incubated in Dulbecco's minimal essential
media (DMEM:F12) supplemented with 10% heat-inactivated fetal
bovine serum (FBS), 100 IU/ml penicillin and 100 IU/ml streptomycin
(P/S) (complete DMEM:F12) for 20 min at 37 °C. The tissue was then
triturated and gently filtered through a sterile mesh filter (40 µm).
This cell suspension was collected by centrifugation for 2000 ×g for
3 min at 20 °C, and the pellet was re-suspended in warm complete
DMEM:F12. Sterile 13-mm plastic coverslips in 24-well culture plates
(Starstedt, Ireland) were pre-coated with poly-L-lysine (60 µg/ml)
and viable cells were seeded at a density of 2×105cells/ml. The mixed
glial cells were cultured in a humidified atmosphere containing 5%
CO2:95% air at 37 °C and the medium was changed every 3 days.
Experiments were performed when the mixed glial cells had been
cultured for 12–14 days. This protocol yields primary mixed glial
cultures containing astrocytes (70%) and microglia (30%) approxi-
mately, as seen by OX-42 (microglial stain) and GFAP (astrocyte stain)
immunocytochemistry (Nolan et al., 2004). Mixed glial cultures were
predominantly used in this study as they give a more appropriate
representation of the in vivo environment than could be achieved
using isolated microglia or astrocytes.
2.2.2. Preparation of cultured primary microglia and astrocytes
Enriched cultures of isolatedmicroglia and astrocyteswere prepared
by seeding mixed glial cells on T25 cm2 tissue culture flasks (Sarstedt,
Ireland) at a density of 2×105cells/ml in completeDMEM:F12 asbefore,supplemented with of GM-CSF (20 ng/ml) and M-CSF (5 ng/ml) (R&D
systems). M-CSF and GM-CSF were included in the growth medium to
stimulate microglial proliferation in order to facilitate harvesting a
sufficient number of microglia for subsequent analyses. The media was
changed after 7 days. On days 12–14 a loosely adherent layer of
microglia was isolated by gentle agitation at 110 rpm for 2 h. The
remaining monolayer of astrocytes was washed with sterile PBS and
aspirated into solution using trypsin–EDTA. Isolated microglia and
astrocytes were centrifuged at 2000 ×g for 3 min at 20 °C and viable
cells were seeded on poly-L-lysine (60 µg/ml) coated 13-mm plastic
coverslips at a density of 2×105cells/ml, and incubated in a humidified
atmosphere containing 5% CO2:95% air at 37 °C. Enriched microglia and
astrocyte cultureswere grown for up to 3–4 days before treatment. This
protocol yields enriched microglial and astrocyte cultures with greater
than 95% purity as assessed using OX-42 (microglial stain) and GFAP
(astrocyte stain) immunocytochemistry.
2.2.3. Preparation of cultured cortical neurons
Primary cortical neurons were isolated and prepared from 1-day-
old Wistar rats (BioResources Unit, Trinity College, Dublin 2, Ireland).
The rats were decapitated, the cerebral cortices were dissected, and
the meninges were removed. The cortices were incubated in PBS with
trypsin (0.25 µg/ml) for 25 min at 37 °C. The cortical tissue was then
triturated in sterile PBS containing soy bean trypsin inhibitor (0.2 µg/
ml) and DNase (0.2 mg/ml) and gently filtered through a sterile mesh
filter (40 µm). The suspensionwas centrifuged at 2000 ×g for 3 min at
20 °C, and the pellet was re-suspended in warm neurobasal media
(NBM), supplemented with heat-inactivated horse serum (10%),
penicillin (100 units/ml), streptomycin (100 units/ml), and glutamax
(2 mM). The suspended cells were plated at a density of 2×105 cells
on circular 10-mm diameter glass coverslips, coated with poly-L-
lysine (60 µg/ml), and incubated in a humidified atmosphere contain-
ing 5% CO2:95% air at 37 °C. After 48 h, 5 ng/ml cytosine-arabinofur-
anoside was added to the culture medium to suppress the
proliferation of non-neuronal cells. The media were changed for
freshmedia every 3 days, and the cells were grown in culture for up to
7 days before treatment. This protocol yields 97% pure cultures of
primary neurons, as demonstrated by Neu-N immunocytochemistry
(Minogue et al., 2003).
2.3. Cell culture treatments
All drugs were dissolved in complete DMEM:F12 (Gibco, Invitro-
gen), whereas control wells received complete DMEM:F12 alone. The
cells were incubated with drugs at the doses and for the durations
outlined in the various experiments below. A dose of 5 μM
noradrenaline was used in most experiments based on pilot studies
conducted in our laboratory, and published results from other
laboratories studying the anti-inflammatory actions of noradrenaline.
We chose equimolar concentrations of α and β-adrenoceptor antag-
onists to combat the actions of noradrenaline. Four to six replicates of
each drug treatment were performed in each experiment. At the end
of the incubation period cells were harvested for RNA isolation, and
cell-free culture supernatants were removed and stored at −80 °C
until cytokine production was determined by ELISA.
2.4. ELISA
IL-1ra and IL-1β concentrations were measured in cell-free
supernatants collected after 6, 12, 24 and 48 h of culture using
ELISA with cytokine specific antibodies and standards obtained from
NIBSC, UK and R&D systems UK respectively. Assays were performed
according to the manufacturer's instructions, and absorbance read at
450 nm using a microplate reader (Biotek instruments). Absorbance
was then recalculated as a concentration (pg/ml) using a standard
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software, Inc).
2.5. Real-time PCR
Total RNA was isolated from glial cells harvested following a 6 h
culture period using a Total RNA isolation kit (Macherney Nagel). Any
genomic DNA contamination was removed with the addition of DNase
to the samples according to themanufacturer's instructions. The yield of
the resulting purified RNA was determined by measurement of the
absorbance at 260 nm in a spectrophotometer, and RNA samples were
subsequently equalised. RNA samples were reverse transcribed into
cDNA using a high capacity cDNA archive kit (Applied Biosystems)
according to the manufacturer's protocol.
Real-time PCR was performed using an ABI Prism 7300 instrument
(Applied Biosystems, Darmstadt, Germany) as previously described
(Boyle and Connor, 2007). Taqman Gene Expression Assays (Applied
Biosystems, Darmstadt, Germany) containing primers and a Taqman
probe were used to quantify each gene of interest. Assay IDs for the
genes examined were as follows: IL-1β (Rn00580432_m1), IL-1ra
(Rn00573488_m1), IL-1RI (Rn00565482_m1), IL-1RII (Rn00588589_m1)
and IL-1RAcp (Rn00492642_m1). PCR was performed in PCR plates in a
20 μl reaction volume (9 μl of diluted cDNA, 1 μl of Taqman Gene
expression assay and 10 μl of Taqman® Universal PCRMaster Mix) and
PCR (40cycles) was run in duplicate using ABIs universal cycling
conditions. β-actin was used as endogenous control to normalize gene
expression data, and an RQ value (2−DDCt, where Ct is the threshold
cycle) was calculated for each sample using Applied Biosystems RQ
software (Applied Biosystems, UK). RQ values are presented as fold
change in gene expression relative to the control group, which was
normalized to 1.
2.6. Western immunoblotting
Serum-free cell cultures were lysed using ice-cold Hepes lysis buffer
(Hepes (25 mM), MgCl2 (5 mM), EDTA (5 mM) in d.d.H2O) with the
addition of DTT (5 mM) and 1% (v/v) of both protease/phosphatase
inhibitors (Sigma, UK). The homogenized cell lysates were centrifuged
at 13,000 rpm for 5 min at 4 °C to pellet the membrane fraction and
insoluble debris. The resultant lysate containing the cytosolic fraction
was assayed for protein content using a BCA protein assay (Pierce) and
diluted to give equal protein concentrations. Samples were diluted 1:2
in sample buffer (0.5 mM Tris–HCl, pH 6.8, 10% glycerol, 10% SDS, 5% β-
mercaptoethanol, and 0.05% w/v bromophenol blue) and boiled for
5 min. 20 µl aliquots were loaded onto 10% polyacrylamide gels.
Proteins were separated by application of a constant voltage of 200 V
for 35 min and then transferred onto nitrocellulose membranes at a
constant voltage of 100 V for 1 h. After blocking in Tris-buffered saline
(TBS)/Tween-20 (150mMNaCl, 50 mM Tris–HCl, and 0.05% v/v Tween
20, pH 7.4) containing bovine serum albumin (BSA) (5% w/v),
membranes were washed in TBS/Tween-20 and incubated in anti-
phospho-extracellular signal-regulated kinase (ERK) [1:2000 in TBS/
Tween-20 containing BSA (1% w/v); Cell Signalling Technology, USA]
overnight at 4 °C. Membranes were washed and incubated in a
horseradish peroxidase-conjugated anti-rabbit IgG [1:3000 in TBS/
Tween-20 containing BSA (1%w/v); AmershamBiosciences, UK] for 1 h
at room temperature before being reacted with Supersignal west dura
chemiluminescent substrate (Pierce), exposed to CL-Xposure X-rayfilm
(Pierce) for up to 20 s, and developed using an automated developer
(Fugi). Initial control experiments determined the optimal time of
exposure to film, which was maintained throughout the experimental
procedure. Protein bands were quantified by densitometric analysis
using Gelworks ID, Version 2.5.1. Gelworks provides a single value (in
arbitrary units) representing the density of each blot.
To analyse total ERK content of the samples, membranes were
stripped of antibody by incubating in reblot plus solution (Chemicon,Temecula, CA), washed, and blocked in TBS/Tween-20 containing BSA
(5% v/v). No bands were detected in stripped blots incubated in
secondary antibody alone, thus verifying the efficacy of the stripping
protocol. Membranes were washed in TBS/Tween-20 and incubated
with anti-ERK [1:2000 in TBS/Tween 20 containing BSA (1%); Cell
Signalling Technology, MA, USA] overnight at 4 °C and then washed
and incubated in a horseradish peroxidase-linked anti-rabbit IgG
[1:3000 in TBS/Tween-20 containing BSA (1% w/v); Amersham
Biosciences] before being reacted with Supersignal solution (Pierce).
Blots were developed and protein bands quantified by densitometric
analysis as outlined above. Phosphorylated ERK1 and ERK2 bands
were normalized to the values of total ERK1 and ERK2 respectively.
Cellular membrane fractions to be analysed for membrane-bound
proteins were incubated with 3-[(3-Cholamidopropyl)dimethylam-
monio]-1-propane sulfonate (CHAPS) buffer (7M Urea, 2M thio Urea
2% (w/v) CHAPS, 65 mM DTT, distilledH2O) and processed as above.
As CHAPS buffer does not allow the use of a BCA protein assay for
equalisation, a Biorad protein assay was performed instead. These
membrane fractions were immunoblotted for IL-1RII protein using
anti-IL-1RII [1:300 in TBS/Tween-20 containing BSA (1% w/v); Santa
Cruz, USA] overnight at 4 °C, followed by incubation with anti-rabbit
IgG [1:1000 in TBS/Tween-20 containing BSA (1% w/v); Amersham
Biosciences, UK] for 1h at room temperature before being reacted
with Supersignal west dura chemiluminescent substrate (Pierce) and
exposed to CL-Xposure X-ray film (Pierce) and bands were quantified
by densometric analysis. Membranes were stripped of antibody and
probedwith a mousemonoclonal IgG antibody that targets rat β-actin
(Sigma, 1:1000 dilution in TBS/Tween 20 containing 2% BSA) and
immunoreactive bands detected using a peroxidase-linked anti-
mouse IgG (1:2000 dilution in TBS/Tween 20 containing 2% BSA).
Again, bands were quantified by densitometric analysis, and IL-1RII
bands were normalized to the values of β-actin.
2.7. Quantification of neuronal cell death
ACytotox 96®Non-Radioactive Cytotoxicity Assay (Promega, UK)was
used to assess the levels of lactate dehydrogenase (LDH) release into the
culture supernatant of treated cells according to the manufacturer's pro-
tocol. Briefly, 2 wells of each culture plate were combined per treatment
group. Total cellular LDH was obtained from adherent primary neuronal
cells by exposing them to 15 µl of lysis solution (9% (v/v) Triton-x-100
in distilled H2O) per 100 µl of culture medium, followed by incubation at
37 ºC for 45 min. 50 μl of media supernatant or cellular lysate was
aspirated fromduplicate treatment and control groups and added to 50 μl
of substrate mix (Kit) for 30 min at 37 ºC. Following this, 50 µl of stop
solutionwas added to arrest the reaction and the absorbance ismeasured
at 490 nm. Percentage cytotoxicity was obtained by expressing LDH
absorbance in the supernatant (released)/LDH absorbance in the cell
lysate (total cellular LDH). Data are expressed as fold-change of released
LDH over media control.
2.8. Statistical analysis of data
All values are expressed as mean±standard error of the mean
(S.E.M.). Datawere analysed using a Student t-test or a one- or two-way
analysis of variance (ANOVA) followed, where appropriate, by a
Newman–Keuls post hoc test (GB-Stat). A P<0.05 was considered
statistically significant.
3. Results
3.1. Noradrenaline induces expression of IL-1ra and IL-1RII in primary
mixed glial cells
Treatment of primary cortical glial cells with noradrenaline (5 µM)
for 6 h significantly increased IL-1ra (P<0.05). Similarly, using ELISA it
Fig. 1. Noradrenaline induced IL-1ra and IL-1RII expression in glial cells. Noradrenaline (5 µM) induces a significant increase in IL-1ra and IL-1RII mRNA expression in primary
cortical mixed glial cells after a 6 h incubation and failed to alter expression of IL-1β, IL-1RI or IL-1RAcp (A and D). The noradrenaline-induced increase of IL-1ra was time and dose-
dependent, with significant effects observed 48 h post-treatment in the 1–10 μM concentration range of noradrenand C). Noradrenaline (5 μM) also induced an increase in
membrane-bound IL-1RII protein after a 24 h treatment (E). Data are expressed as mean±S.E.M. (n=4–6). (A, D and E) *P<0.05, **P<0.01 vs. control (Student t-test), (B and C)
*P<0.05, **P<0.01 vs. control (Newman–Keuls test).
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tion which was maximal 48 h following treatment (Fig. 1C), and this
increase in IL-1ra production observed at 48 h occurred in a dose-
dependent manner, with noradrenaline (1–10 μM) eliciting significant
effects (Fig. 1B). Treatment of primary cortical glial cells with
noradrenaline (5 µM) for 6 h significantly also increased IL-1RII
(P<0.01) mRNA expression. Similarly, using Western immunoblotting
it was demonstrated that treatment with noradrenaline (5 μM)
increased IL-1RII protein expression (Fig. 1E). In contrast, noradrenalinetreatment failed to alter IL-1β expression/production or expression of
IL-1RI or IL-1RAcp (Fig. 1A–D).
3.2. β-adrenoceptors mediate the ability of noradrenaline to induce
IL-1Ra and IL-1RII in primary mixed glial cells
As previous literature has identified the β-adrenoceptor in
mediating the anti-inflammatory properties of noradrenaline in vitro
(Feinstein, 1998; Feinstein et al., 2002; Frohman et al., 1988; Galea
223E.N. McNamee et al. / European Journal of Pharmacology 626 (2010) 219–228et al., 2003), the following studies were carried out to determine
which adrenoceptor subtype mediated the ability of noradrenaline to
induce IL-1ra and IL-1RII expression in glial cells. Pre-treatment of the
primary glia with the α-adrenoceptor antagonist, phentolamine
(5 μM) failed to attenuate the ability of noradrenaline to induce IL-
1ra and IL-1RII expression (Fig. 2A–B). Conversely, pre-treatment
with the β-adrenoceptor antagonist propranolol (5 μM) for 30 min
significantly blocked noradrenaline-induced IL-1ra and IL-1RII ex-
pression (P<0.01) (Fig. 2C–D). Furthermore, treatment of glial cells
with the selective β2-adrenoceptor agonist salmeterol (0.1–10 µM)
mimicked the ability of noradrenaline to induce IL-1ra (P<0.01) and
IL-1RII (P<0.01) expression (Fig. 2E–F). Whilst treatment of glial cells
with the selective β1-adrenoceptor agonist, xamoterol (1–10 μM)
increased IL-1ra mRNA expression (P<0.01) it failed to induce IL-1RII
expression (Fig. 2E–F).
3.3. A role for the cAMP–PKA pathway and ERK activation in the ability
of noradrenaline to induce IL-1Ra and IL-1RII in primary mixed glial cells
Consistent with the ability of β-adrenoceptors to activate the
cAMP–PKA pathway, treatment of mixed glial cells with the lipophilic
cAMP analogue, db-cAMP (100 μM) for 6 h, significantly induced
expression of IL-1ra (P<0.01) and IL-1RII (P<0.01) (Fig. 3A–B).
Conversely, a 30 min pre-treatment with the selective PKA antagonist,
KT5720 (1 μM), attenuated the noradrenaline (5 μM)-induced increase
in IL-1ra (P<0.05) and IL-1RII (P<0.01) expression (Fig. 3C–D).
Activation of the mitogen activated protein kinase (MAPK),
extracellular response kinase (ERK), by either noradrenaline orFig. 2. β-adrenoceptors mediate the ability of noradrenaline to induce IL-1ra and IL-1RII exp
α-adrenoceptor antagonist, phentolamine (5 μM) failed to block noradrenaline (5 µM)-induc
selective β-adrenoceptor antagonist, propranolol (5 µM) attenuated the noradrenaline-induced
salmeterol (0.1–10 µM) induced a significant increase in IL-1ra and IL-1RIImRNA expression fro
agonist xamoterol (1 µMand 10 µM) induced a significant increase in IL-1ra, but failed to alter IL
media control (n=6). *P<0.05, **P<0.01 vs. control, ++P<0.01 vs. noradrenaline (5 µM) (NcAMP-inducing agents has previously been shown to be neuropro-
tective (Chen et al., 2007; Troadec et al., 2002). Consequently, in this
study the involvement of ERK in the noradrenaline-induced increase
in IL-1ra and IL-1RII was assessed. Consistent with the previous
literature, noradrenaline induced an increase in ERK phosphorylation
in primary mixed glial cultures via β-adrenoceptor activation, as pre-
treatment with the β-adrenoceptor antagonist, propranolol, inhibited
this increase (P<0.05) (Fig. 4A). As MEK1/2 is directly upstream of
ERK and induces ERK phosphorylation, we examined the ability of the
selective MEK1/2 inhibitor U0126 to inhibit the induction of IL-1ra
and IL-1RII induced by noradrenaline. Consistent with a role for ERK in
the ability of noradrenaline to induce IL-1ra and IL-1RII, a 30 min pre-
treatment of primary glial cells with U0126 (10 μM), inhibited
noradrenaline-induced IL-1ra (P<0.01) and IL-1RII (P<0.05) mRNA
expression (Fig. 4B–C).
3.4. Noradrenaline induces IL-1ra and IL-1RII expression in enriched
microglial cultures but not in enriched astrocyte cultures
As the mixed preparation of primary glial cells used in these
experiments best represents the glia cell ratio in vivo, it was proposed
that this would be the optimum in vitro system to assay the basal
expression of inflammatory cytokines and receptors, induced by
noradrenaline. However, previous literature has identified microglia
as being thepredominant producer of IL-1 ligands and the sole producer
of IL-1ra in the CNS (Liu et al., 1998; Pinteaux et al., 2006). To clarify the
source of IL-1 ligands and receptors induced by noradenaline in mixed
glia, primary cultures of enriched microglia and astrocytes wereression in glial cells. Pre-treatment of primarymixed glial cells with the non-selective
ed expression of IL-1ra and IL-1RII (A and B). Conversely, pre-treatment with the non-
increase in IL-1ra and IL-1RII expression (C and D). The selective β2-adrenoceptor agonist
mprimarymixed glial cells after a 6 h incubation (E and F). The selective β1-adrenoceptor
-1RIImRNAexpression (E and F). Data are expressed asmean±S.E.M. as fold-change over
ewman–Keuls test).
Fig. 3. Activation of the cAMP/protein kinase A pathway mediates the noradrenaline-induced increase in glial IL-1ra and IL-1RII expression. Treatment with the cAMP analogue
dbcAMP (100 µM) induced a significant increase in IL-1ra and IL-1RII mRNA expression from primary mixed glial cells (A and B). Pre-treatment with selective PKA antagonist,
KT5720 (1 μM) attenuated noradrenaline (5 μM)-induced IL-1ra and IL-1RII expression. Data are expressed as mean±S.E.M. as fold-change over media control (n=6). (A and B)
**P<0.01 vs. media control (Student t-test). (C and D) *P<0.05, **P<0.01 vs. control, +P<0.05, ++P<0.01 vs. noradrenaline (Newman–Keuls test).
Fig. 4. A role for ERK in the noradrenaline-induced increase in IL-1ra and IL-1RII expression in glial cells. A 15 min treatment with noradrenaline (5 μM) increased ERK
phosphorylation in glial cells, and this increase was blocked by pre-treatment with the β-adrenoceptor antagonist propranolol (5 μM) (A). In addition, pre-treatment with
the selective Mek 1/2 antagonist, U0126 (10 μM) attenuated the noradrenaline-induced increase in IL-1ra and IL-1RII expressions (B and C). Data are expressed as mean+S.E.M.
(n=5–6). *P<0.05, **P<0.01 vs. control, ++P<0.01, +P<0.05 vs. noradrenaline (Newman–Keuls test).
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expressions. The results demonstrated that noradrenaline (5 µM)
significantly induced mRNA expression of IL-1ra (P<0.05) and IL-1RII
(P<0.05) in enrichedmicroglial cultures, but not in enriched astrocytes
cultures (Fig. 5A–D).
3.5. Noradrenaline induces IL-1ra and IL-1RII expression in primary
mixed glial cells in the presence of an inflammatory stimulus (IL-1β)
Under pathological conditions glial cells in the central nervous
system may have already been exposed to IL-1β (Allan et al., 2005),
thus it was important to determine if noradrenaline could induce
expression of IL-1ra and IL-1RII in glial cells exposed to IL-1β. The
results demonstrated that noradrenaline was equally as effective at
inducing IL-1ra and IL-1RII in cells treated with IL-1β (5 ng/ml) as it
was in unstimulated glial cells (Fig. 6A–B). In contrast, noradrenaline
failed to alter the significant (P<0.01) induction of IL-1RI expression
induced by IL-1β treatment (Fig. 6D), but significantly (P<0.01)
attenuated IL-1β-induced IL-1β expression (Fig. 6C).
3.6. Noradrenaline inhibits IL-1β-induced neurotoxicity
It has been previously demonstrated that IL-1β is not directly
neurotoxic to healthy neurons in vitro, but can induce neurotoxicity by
increasing glial-derived neurotoxic agents such as reactive nitrogen
species, free radicals, and inflammatory cytokines (Rothwell, 2003; Ma
and Zhao, 2002; Thornton et al., 2006). As such, the following studywas
carried out to asses the ability of noradrenaline to limit neurotoxicity in
primary cortical neurons treated with conditioned media from IL-1β
stimulated glial cells. A dose of 5 ng/ml of IL-1βwas employed based on
previous studies which established the ability of IL-1β-stimulated glial
cells to elicit neurotoxicity (Thornton et al., 2006). Primary corticalFig. 5. Noradrenaline induces IL-1ra and IL-1RII expression in microglia but not astrocytes. N
of enriched cortical microglia 6 h post-treatment (A and C). Noradrenaline failed to alter IL-
expressed as mean±S.E.M. (n=4). *P<0.05 vs. control (Student t-test).mixed glial cells were treated for 48 h with either a media vehicle or
noradrenaline (5 µM) followed by a 24 h treatment with recombinant
IL-1β (5 ng/ml). This glial-conditioned media (CM) was added to
primary cortical neuronal cells for 48 h. As a control, primary neurons
were also treatedwith IL-1β (5 ng/ml) to asses the direct effects of IL-1β
on neuronal toxicity. IL-1β (5 ng/ml) had no significant direct affect on
neuronal toxicity (asmeasured by LDH release) (Fig. 7). However, IL-1β
(5 ng/ml)-conditioned glial media significantly induced neuronal cell
death at a 48 h time-point (P<0.01) and this was attenuated by pre-
treatment with noradrenaline (5 µM) (P<0.01) (Fig. 7). Treatment of
neurons with noradrenaline (5 μM) alone did not alter neuronal
viability (data not shown).4. Discussion
The major finding of this study is that the monoamine neuro-
transmitter noradrenaline induced expression of two negative
regulators of the IL-1 system (IL-1ra and IL-1RII) in primary mixed
glial cell cultures. The importance of IL-1ra in regulating the actions of
IL-1β has become apparent in recent years after it was shown that an
endogenous imbalance between IL-1ra and IL-1β is of pathophysio-
logical significance in peripheral inflammatory disorders including
rheumatoid arthritis and inflammatory bowel disease (Palin et al.,
2004). IL-1ra is generally found to be up-regulated in a dose-
dependent manner with IL-1β to dampen down the inflammatory
effects of IL-1β over-expression (Palin et al., 2004). However in this
study it is noteworthy that the increase in glial IL-1ra production
induced by noradrenaline does not occur secondary to IL-1β
production, as IL-1β production was not altered by noradrenaline.
Thus it appears that noradrenaline induces a selective upregulation of
IL-1ra; the anti-inflammatory ligand in the IL-1 system. In conjunction
with inducing IL-1ra, our results demonstrate that noradrenalineoradrenaline (5 μM) induced an increase in IL-1ra and IL-1RII mRNA in primary cultures
1ra or IL-1RII expression in primary cultures of enriched astrocytes (B and D). Data are
Fig. 6. Noradrenaline induces glial IL-1ra and IL-1RII expression in the presence of an inflammatory stimulus (IL-1β). Noradrenaline (5 μM) induced expression of IL-1ra and IL-1RII
mRNA in both unstimulated glial cells, and glial cells treated with IL-1β (5 ng/ml) (A and B) for 6 h. Noradrenaline failed to alter the IL-1β-induced increase in IL-1RI expression
(D), but attenuated IL-1β-induced IL-1β expression (C). Data are expressed as mean+S.E.M. (n=5–6). *P<0.05, **P<0.01 vs. control counterparts, +P<0.05, ++P<0.01 vs.
unstimulated counterparts (Newman–Keuls test).
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significant, as IL-1RII is a decoy receptor that serves to sequester IL-1
and therefore like IL-1ra is a negative regulator of the IL-1 system.
However, it must be noted that the observed increase in IL-1RII
protein expression tends to be much lesser in magnitude than whatFig. 7. Noradrenaline inhibits neurotoxicity in primary cortical neurons induced by
conditioned media from IL-1β-stimulated glial cells. Treatment of neurons alone with
IL-1β (5 ng/ml) did not induce neurotoxicity (LDH release). In contrast, treatment of
neurons with conditioned media from IL-1β-treated mixed glial cells (CM) induced a
neurotoxic response as measured by a significant increase in LDH release. This
neurotoxic action of conditioned media from IL-1β treated glial cells was not evident if
glial cells were pre-treated with noradrenaline (5 µM) prior to IL-1β exposure. Data are
expressed as mean±S.E.M. (n=4). **P<0.01 vs. control CM-neurons, ++P<0.01 vs.
IL-1β CM-neurons (Newman–Keuls test).we observe at the mRNA level. It is also noteworthy that noradren-
aline is equally as effective at inducing IL-1ra and IL-1RII in the
presence of an inflammatory stimulus, (IL-1β), as it is in unstimulated
glial cells. This is an important finding, as under pathological
conditions glial cells in the central nervous system can be exposed
to IL-1β (Allan et al., 2005).
It is clear from our studies that induction of IL-1ra and IL-1RII by
noradrenaline is mediated by activation of β-adrenoceptors. Specif-
ically, induction of IL-1ra and IL-1RII by noradrenaline was completely
blocked by the β-adrenoceptor antagonist propranolol. Furthermore,
the selective β2-adrenoceptor agonist salmeterol, mimicked the NA-
induced increase IL-1ra and IL-1RII production. Whilst the β1-
adrenoceptor agonist, xamoterol, increased IL-1ra expression it failed
to induce expression of IL-1RII. These data are consistent with the fact
that both β1- and β2-adrenoceptors are expressed on glia, however,
β2-adrenoceptors are more abundantly expressed on microglia and
produce greater amounts of cAMP upon stimulation with agonist than
β1-adrenoceptors (Mori et al., 2002). These data are also concordant
with previous reports indicating that activation of β-adrenoceptors on
glial cells provides protection from inflammatory insults (Junker et al.,
2002) and decreases LPS-induced pro-inflammatory cytokine pro-
duction (Dello Russo et al., 2004; Mori et al., 2002).
Consistent with the ability of β-adrenoceptors to activate
adenylate cyclase and up-regulate intracellular cAMP, the lipophilic
cAMP analogue, db-cAMP, increased both IL-1ra and IL-1RII expres-
sion. Furthermore, as protein kinase A (PKA) is a major intracellular
target for cAMP, it is noteworthy that the selective PKA inhibitor,
KT5720, blocked the noradrenaline-induced increase in IL-1ra and IL-
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receptors, such as the β-adrenoceptor, activate ERK-1 and -2, either
downstream of secondmessengers like cAMP and Ca2+ or, that the Gα-
and/or Gβγ-subunits may directly or indirectly activate the Ras/Raf
pathway upstream of ERK through adapter proteins, tyrosine kinases
(Faure et al., 1994; Kolch, 2005; Lopez-Ilasaca, 1998). Activation of ERK
by either noradrenaline or cAMP-inducing agents has previously been
shown to be neuroprotective by inducing brain-derived neurotrophic
factor (BDNF) from hippocampal neurons as well as protecting
dopaminergic neurons from oxidative stress-induced toxicity (Chen
et al., 2007; Troadec et al., 2002). Consequently, the involvement of ERK
in mediating the noradrenaline-induced increases in IL-1ra and IL-1RII
was assessed. Consistent with the previous literature, noradrenaline
induced an increase in ERK phosphorylation in primary mixed glial
cultures via β-adrenoceptor activation, indicated by the fact that the
β-adrenoceptor antagonist, propranolol, inhibited this increase.
Moreover, treatment of glial cells with the MEK inhibitor, U0126,
inhibited noradrenaline-induced IL-1ra and IL-1RII mRNA expres-
sions. In all these data indicate that activation of the ERK pathway
downstream of β-adrenoceptor activation mediates the induction of
IL-1ra and IL-1RII induced by noradrenaline.
In an effort to identify the cellular source of the noradrenaline-
induced IL-1ra and IL-1RII expressions from mixed glial in vitro,
enriched cultures of both microglia and astrocytes were treated with
noradrenaline under the same conditions. Our results indicate that
microglia are the sole producer of IL-1ra and IL-1RII, as astrocytes failed
to respond to treatment with noradrenaline. At least where IL-1ra is
concerned, this is consistent with previous literature which has
identified microglia as being the predominant producer of IL-1 ligands
and the sole producer of IL-1ra in theCNS(Liu et al., 1998; Pinteauxet al.,
2006). The magnitude of IL-1RII and IL-1ra expression induced by
noradrenaline in enrichedmicroglial cells is much less than observed in
mixed glial cells, and this may be due to differences in experimental
procedures. Specifically, the growth factorsM-CSF andGM-CSF are used
in the preparation of enriched microglia in order to yield a sufficient
number of microglia for analysis. This growth factor cocktail induces a
large reduction in β2-adrenoceptor expression onmicroglia (Ryan et al.,
unpublished data), and we suggest that this reduction in β2-adreno-
ceptors impairs the ability of noradrenaline to induce IL-1RII and IL-1ra
expressions in enrichedmicroglial cells relative tomixedglial cultures. It
is also possible that induction of IL-1RII and IL-1ra expression by
noradrenaline from microglial cells may require an as yet unidentified
juxtacrine factor present in mixed glial cultures.
Previous literature demonstrates that IL-1β is not directly
neurotoxic to healthy neurons in vitro, but rather, exacerbated
neuronal damage by increasing glial-derived agents such as reactive
nitrogen species, free radicals, and inflammatory cytokines (Rothwell,
2003; Ma and Zhao, 2002; Thornton et al., 2006). Considering the
ability of noradrenaline to induce expression of IL-1ra and IL-1RII we
examined the ability of noradrenaline to limit neuronal toxicity
induced by conditioned media harvested from IL-1β treated mixed
glial cells. In the present study, treatment of primary cortical neurons
with IL-1β did not elicit neurotoxic effects as measured by LDH
release. However, addition of conditioned media from IL-1β-stimu-
lated mixed glial cells to neurons induced neurotoxicity indicated by
an increase in LDH release. Treatment of glial cells with noradrenaline
prior to addition of IL-1β, attenuated the neurotoxic effects of
conditioned media from IL-1β-treated glial cells. These data are
consistent with a previous study where pre-treatment with nor-
adrenaline inhibited neurotoxicity in cultured cortical neurons
induced by conditioned media from LPS-stimulated microglial cells
(Madrigal et al., 2005).
The results presented here demonstrate that noradrenaline by
activation glial β-adrenoceptors induces expression of two negative
regulators of the IL-1 system (IL-1ra and IL-1RII) in glial cells.
Furthermore, this expression of IL-1ra and IL-1RII is accompanied byprotection against IL-1β-induced neurotoxicity. These results suggest
that noradrenaline may elicit its endogenous anti-inflammatory and
neuroprotective effects by increasing expression of IL-1ra and IL-1RII in
the CNS. These datamay partially explain why the loss of noradrenergic
Locus Ceruleus neurons, and subsequent central noradrenergic tone,
contributes to inflammatory activation in chronic inflammatory states
such as Alzheimer's disease (Heneka et al., 2003). Of course a limitation
of the present study is that is it performed entirely using cultured glial
cells prepared from neonatal rats, and we don't yet know how these
findings translate into the in vivo setting. Future studies will examine
the impact of noradrenaline enhancing agents and β2-adrenoceptor
agonists on expression of IL-1ra and IL-1RII in glial cells in the intact CNS
of adult animals.
While recombinant human IL-1ra is now a licensed subcutaneous
treatment for rheumatoid arthritis (Cohen et al., 2002; Bresnihan et al.,
1998) and is in a phase II clinical trials using intravenous infusions for
stroke patients (Rothwell, 2003), at 17 kDa, IL-1ra is a large protein and
is likely to have limited blood brain barrier permeability. Thus,
pharmacological intervention that would increase the CNS expression
levels of IL-1ra and/or IL-1RII may prove to be a beneficial alternative to
peripheral administration of the recombinant protein. Considering the
ability of physiologically relevant doses of noradrenaline to induce both
IL-1ra and IL-1RII in vitro, we suggest that activation of the central
noradrenergic system may be of therapeutic potential in neuroinflam-
matory conditions. In this regard, studies are ongoing to examine the
ability of pharmacological agents that increase central noradrenergic
tone to protect against inflammation-related neurodegeneration.Acknowledgements
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